Keeler Thomas Management’s ResMed RMD Stock Holding History

Keeler Thomas Management’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.26M	Buy	10,081 +4,725	+88%	+$1.18M	0.96%	39
2025 Q4	$1.29M	Buy	5,356 +7	+0.1%	+$1.79K	0.61%	54
2025 Q3	$1.46M	Buy	5,349 +70	+1%	+$19.1K	0.6%	52
2025 Q2	$1.36M	Buy	+5,279	New	+$1.26M	0.59%	52

Other funds holding RMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Keeler Thomas Management's RMD Position: Q1 2026 in Review

Keeler Thomas Management increased its ResMed (RMD) stake by 88% in Q1 2026, buying an estimated $1.18M and bringing the position to 10,081 shares worth $2.26M. The position accounts for 0.96% of the portfolio, ranked #39.

Keeler Thomas Management first reported a position in RMD in Q2 2025 and has held it in 4 quarters since. 938 funds tracked by Wall St. Rank hold RMD as of Q1 2026.

Keeler Thomas Management held 10,081 shares of ResMed worth $2.26M as of Q1 2026.
Keeler Thomas Management bought 4,725 ResMed shares in Q1 2026, an estimated $1.18M.
ResMed made up 0.96% of Keeler Thomas Management's portfolio in Q1 2026, its #39 holding.
Keeler Thomas Management first reported a position in ResMed in Q2 2025 and has held it in 4 quarters since.
938 funds tracked by Wall St. Rank held ResMed as of Q1 2026.

Based on Keeler Thomas Management's 13F filing for Q1 2026, filed 12 May 2026.